Dawne Rowe Haas

Dawne Rowe Haas

Auto-generated profile, based on publicly available information

Dawne Rowe Haas

Department of Infectious Diseases, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
DADong An
Dong An
KLKun Li
Kun Li
DRDawne K. Rowe
Dawne K. Rowe
MDMaria Cristina Huertas Diaz
Maria Cristina Huertas Diaz
EGEmily Griffin
Emily Griffin
BHBiao He
Biao He
Single-dose intranasal COVID-19 vaccine prevents infection and inhibits transmission.

28 March 2025 in Science Advances
Verified
Journal Article
Open access
CPCaroline Katherine Page
Caroline Katherine Page
JSJustin D. Shepard
Justin D. Shepard
SRSean D. Ray
Sean D. Ray
JFJames A. Ferguson
James A. Ferguson
ARAlesandra J. Rodriguez
Alesandra J. Rodriguez
Stephen Mark TompkinsStephen Mark Tompkins
Stephen Mark Tompkins
The two influenza B virus (FLUBV) lineages have continuously diverged from each other since the 1980s, with recent (post-2015) viruses exhibiting accelerated evolutionary rates. Emerging data from human studies and epidemiological models suggest that increased divergence in contemporary viruses may drive differential cross-protection, where infection with Yamagata lineage viruses provides limited immunity against Victoria lineage viruses. Here, we developed animal models to investigate the mechanisms behind asymmetric cross-protection between contemporary FLUBV lineages. Our results show that contemporary Victoria immunity provides robust cross-protection against the Yamagata lineage, whereas Yamagata immunity offers limited protection against the Victoria lineage. This differential cross-protection is driven by Victoria-elicited neuraminidase (NA)–specific antibodies, which show cross-lineage reactivity, unlike those from Yamagata infections. These findings identify a phenomenon in contemporary FLUBV that may help explain the recent disappearance of the Yamagata lineage from circulation, highlighting the crucial role of targeting NA in vaccination strategies to enhance cross-lineage FLUBV protection.

23 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
DLDeanna N. Lanier
Deanna N. Lanier
DHDawne Rowe Haas
Dawne Rowe Haas
MUMario Uchimiya
Mario Uchimiya
CJCheryl Jones
Cheryl Jones
SJScott Johnson
Scott Johnson
Arthur EdisonArthur Edison
Arthur Edison
This study evaluates the impact of PFOA exposure on the metabolome and immune response to SARS-2 using a ferret model. Ferrets were separated into control or PFOA-exposed groups (10/mg/kg/day) and challenged with SARS-2. Longitudinal analyses encompassing clinical assessments, serological profiling, histopathology, and untargeted nuclear magnetic resonance (NMR) metabolomics revealed significant metabolic and immunological perturbations. We found prominent effects of PFOA exposure on metabolism, which resulted in altered metabolic responses to SARS-2 infection. PFOA exposure was also associated with impaired immune function, as evidenced by decreased serum IgG levels, increased viral loads, and prolonged peak infectivity. These findings underscore the consequences of PFOA exposure on host metabolism and immunity during infectious diseases.

31 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
DHDawne Rowe Haas
Dawne Rowe Haas
SJScott K. Johnson
Scott K. Johnson
CJCheryl A. Jones
Cheryl A. Jones
MWMin-Xuan Wang
Min-Xuan Wang
EMErin A. Miller
Erin A. Miller
Stephen Mark TompkinsStephen Mark Tompkins
Stephen Mark Tompkins
Live Attenuated Influenza Vaccines (LAIV) are attenuated, temperature sensitive, and cold adapted to limit replication to the upper respiratory tract. This modification seeks to prevent clinical disease while effectively eliciting the development of immunity. While LAIVs offer benefits over Inactivated Influenza Vaccines (IIV), thermostability remains a key concern. Using Preservation By Vaporization (PBV), we have established a thermostable LAIV (tLAIV) that is stable at ambient temperature for at least one year and suitable for respiratory delivery in a dry powder form. Using the ferret model, we have demonstrated that tLAIV elicited protective immune responses to subsequent influenza virus infection. Here, we expand on these studies to confirm the safety of tLAIV following intranasal administration. Continuing with the ferret model, we completed a dose-response safety and immunogenicity study of tLAIV formulated both with and without Advax adjuvant and compared the results to those of liquid LAIV controls. Dry-powder vaccination with tLAIV or LAIV did not cause significant temperature elevations, lethargy, weight loss, or other clinical changes. Clinical chemistry and complete blood counts (CBC) remained within established baseline reference ranges. On histopathology, there were no adverse effects seen on the upper or lower respiratory tract 14 days after vaccine delivery. ELISA and hemagglutination inhibition assays (HAI) confirmed seroconversion was induced by all vaccine formulations, with neither dose nor adjuvant improving the magnitude of response. Nasal wash analysis demonstrated that PBV- stabilized tLAIV exhibited comparable infectivity to the same dose of liquid LAIV control. These findings further reinforce the similarity in infectivity, immunogenicity, and safety of intranasal vaccination using PBV-tLAIV, both with and without an adjuvant.